Quick Takeaways
- Paradigm Biocapital Advisors LP filed SCHEDULE 13G/A for UroGen Pharma Ltd. Ordinary Shares, par value NIS 0.01 per share (URGN).
- Disclosed ownership: 9%.
- Date of event: 30 Sep 2025.
Paradigm Biocapital Advisors LP - 30 Sep 2025 SCHEDULE 13G/A Report for UroGen Pharma Ltd. Ordinary Shares, par value NIS 0.01 per share (URGN)
- Filing Manager
- Paradigm Biocapital Advisors LP
- Reporting Manager
- Paradigm BioCapital Advisors LP
- Symbol
- URGN
- Shares outstanding
- 46,845,378 shares
- Disclosed Ownership
- 4,216,084 shares
- Ownership
- 9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 16:31:47 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 12 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Paradigm Biocapital Advisors LP disclosed 9% ownership in UroGen Pharma Ltd. Ordinary Shares, par value NIS 0.01 per share (URGN) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 12 Aug 2025.
- Current filing was accepted on 14 Nov 2025, 16:31.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Paradigm BioCapital Advisors LP | 9% | 4,216,084 | 4,216,084 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory | |
| Paradigm BioCapital Advisors GP LLC | 9% | 4,216,084 | 4,216,084 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory | |
| Senai Asefaw, M.D. | 9% | 4,216,084 | 4,216,084 | 0 | /s/ Senai Asefaw, M.D. | N/A | |
| Paradigm BioCapital International Fund Ltd. | 8% | 3,722,066 | 3,722,066 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory |